nach oben

International Urology and Nephrology

Erschienen in:

13.05.2020 | Nephrology - Original Paper

Lymphocyte and monocyte vitamin D receptor expression during paricalcitol or calcitriol treatments in patients with stage 5 chronic kidney disease

verfasst von: Hasan Sözel, Sadi Köksoy, Sebahat Ozdem, Fatih Yılmaz, Feyza Bora, F. Fevzi Ersoy

Erschienen in: International Urology and Nephrology | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

In this study, we aimed to investigate the effect of paricalcitol and calcitriol usage on vitamin D receptor (VDR) contents of CD8+ , CD4+ lymphocytes and monocytes in stage 5d chronic kidney disease (CKD) patients.

Methods

Thirty-six hemodialysis patients older than 18 years of age and 19 healthy controls (group HC) without any known acute or chronic diseases were included in the study. The group of patients undergoing scheduled hemodialysis comprised three subgroups: group CL: patients on calcitriol (n: 10), group PC: patients on paricalcitol (n: 13), and group NT: patients not taking any vitamin D or VDR activating medications (n: 13). CD8+/VDR, CD4+/VDR and MONO/VDR values were representing the ratio of VDR representing cells among related cell group. On the other hand, values of CD8+/MFI, CD4+/MFI and MONO/MFI have shown the total amount of cellular VDR content per cell which has been given as of mean fluorescence intensity in the flow cytometric process. Main CKD mineral bone disorder parameters such as a hemogram, serum BUN, creatinine, albumin, Ca, iP, iPTH, 25(OH)D₃ levels were also measured.

Results

Average VDR contents in CD8+, CD4+ and monocytes were not different among three patient groups on hemodialysis. But in all hemodialysis subgroups, CD8+/VDR, CD4+/VDR, MONO/VDR, CD8+/MFI, CD4+/MFI and MONO/MFI levels were found to be higher compared with the healthy control subjects (p < 0.001). Among hemodialysis groups, no significant CD8+/VDR, CD4+/VDR, and MONO/VDR content differences were found with regard to the type of VDR activator agent used. There was no difference in serum levels of 25(OH)D₃ and CRP among groups participating in the study.

Conclusion

There was no difference between CD8+/VDR, CD4+/VDR, and MONO/VDR levels in hemodialysis patients using calcitriol or paricalcitol, suggesting that both treatment agents may have a similar effect on VDR contents in lymphocytes and monocytes in that patient population. But in all hemodialysis subgroups, CD8+/VDR, CD4+/VDR, and MONO/VDR levels were found to be higher compared with the healthy control subjects, suggesting an overexpression of VDR through a non CRP and/or 25(OH)D₃ dependent mechanism.

Bolton CH, Downs LG, Victory JG, Dwight JF, Tomson CR, Mackness MI et al (2001) Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol Dial Transplant 16(6):1189–1197CrossRef

Sarnak MJ, Levey AS (2000) Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis 35(4 Suppl 1):117–131CrossRef

Stenvinkel P (2002) Inflammation in end-stage renal failure: could it be treated? Nephrol Dial Transplant 17(Suppl 8):33–38CrossRef

Akchurin OM, Kaskel F (2015) Update on inflammation in chronic kidney disease. Blood Purif 39(1–3):84–92CrossRef

Holick MF, Chen TC (1080S) Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr 87(4):1080S–S1086CrossRef

van Etten E, Mathieu C (2005) Immunoregulation by 1, 25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol 97(1–2):93–101CrossRef

Maalouf NM (2008) The non-calciotropic actions of vitamin D: recent clinical developments. Curr Opin Nephrol Hypertens 17(4):408–415CrossRef

Hochberg ZE (2003) Vitamin D and rickets. Karger Medical and Scientific Publishers, Basel (e-ISBN: 978-3-318-00975-0) CrossRef

Liu C, Li H (2019) Correlation of the severity of chronic kidney disease with serum inflammation, osteoporosis and vitamin D deficiency. Exp Ther Med 17(1):368–372PubMed

10.

Lopez-Munoz P, Beltran B, Saez-Gonzalez E, Alba A, Nos P, Iborra M (2019) Influence of vitamin D deficiency on inflammatory markers and clinical disease activity in IBD patients. Nutrients. 11:5CrossRef

11.

Lucas RM, Gorman S, Geldenhuys S, Hart PH (2014) Vitamin D and immunity. F1000Prime Rep 6:118CrossRef

12.

Özkan B, Döneray H (2011) D vitamininin iskelet sistemi dişi etkileri. Cocuk Sagligi Hastaliklari Dergisi 54(2):99–119

13.

Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, Selznick SH et al (1998) The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 13(3):325–349CrossRef

14.

Zhang Y, Leung DY, Richers BN, Liu Y, Remigio LK, Riches DW et al (2012) Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. J Immunol. 188(5):2127–2135CrossRef

15.

Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C (2010) Vitamin D: modulator of the immune system. Curr Opin Pharmacol 10(4):482–496CrossRef

16.

Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP (2002) 1, 25-Dihydroxyvitamin D 3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110(2):229–238CrossRef

17.

Vaziri ND (2004) Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Curr Opin Nephrol Hypertens 13(1):93–99CrossRef

18.

Welsh J (2012) Cellular and molecular effects of vitamin D on carcinogenesis. Arch Biochem Biophys 523(1):107–114CrossRef

19.

Sugden JA, Davies JI, Witham MD, Morris AD, Struthers AD (2008) Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. Diabet Med 25(3):320–325CrossRef

20.

Sanz AB, Izquierdo MC, Sanchez-Nino MD, Ucero AC, Egido J, Ruiz-Ortega M et al (2014) TWEAK and the progression of renal disease: clinical translation. Nephrol Dial Transplant 29(Suppl 1):i54–i62CrossRef

21.

Gupta J, Mitra N, Kanetsky PA, Devaney J, Wing MR, Reilly M et al (2012) Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol 7(12):1938–1946CrossRef

22.

Almeida ACSF, Siqueira MC, Bonan NB, Dambiski A, Bertuzzo G, Moreno-Amaral AN et al (2019) Vitamin D levels reverberate in monocytes modulation in hemodialysis patients. J Cell Physiol. 2019:25. https://doi.org/10.1002/jcp.28290 CrossRef

23.

Ateş I, Ozkayar N, Yılmaz FM, Bayrakçı N, Neselioğlu S, Erel O et al (2018) Oxidative stress level in patients with chronic kidney disease. Ortadogu Med J 10(1):45–50

24.

Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA et al (2007) Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71(1):31–38CrossRef

25.

Graeff-Armas LA, Kaufmann M, Lyden E, Jones G (2018) Serum 24, 25-dihydroxyvitamin D3 response to native vitamin D2 and D3 Supplementation in patients with chronic kidney disease on hemodialysis. Clin Nutr 37(3):1041–1045CrossRef

26.

Ogunkolade BW, Boucher BJ, Prahl JM, Bustin SA, Burrin JM, Noonan K et al (2002) Vitamin D receptor (VDR) mRNA and VDR protein levels in relation to vitamin D status, insulin secretory capacity, and VDR genotype in Bangladeshi Asians. Diabetes 51(7):2294–2300CrossRef

27.

Peacock M (2010) Calcium metabolism in health and disease. Clin J Am Soc Nephrol 5(Suppl 1):23–30CrossRef

28.

Çidem M, Karacan İ, Beytemur O, Kara S (2017) Prevalence and risk factors for vitamin D deficiency in patients with widespread musculoskeletal pain. Turk J Med Sci. 47(3):728–731CrossRef

Titel: Lymphocyte and monocyte vitamin D receptor expression during paricalcitol or calcitriol treatments in patients with stage 5 chronic kidney disease
verfasst von: Hasan Sözel
Sadi Köksoy
Sebahat Ozdem
Fatih Yılmaz
Feyza Bora
F. Fevzi Ersoy
Publikationsdatum: 13.05.2020
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 8/2020
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-020-02475-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2020

Systemic immune inflammation index is a promising non-invasive marker for the prognosis of the patients with localized renal cell carcinoma

Correction to: Interleukin 6 is a better predictor of 5-year cardiovascular mortality than high-sensitivity C-reactive protein in hemodialysis patients using reused low-flux dialyzers

Importance of long-term follow-up after endoscopic management for upper tract urothelial carcinoma and factors leading to surgical management

Evaluation of serum fatty acid binding protein-4 (FABP-4) as a novel biomarker to predict biopsy outcomes in prostate biopsy naïve patients

Smoke load prognostic impact on bacillus Calmette–Guérin (BCG) treated non-muscle invasive bladder cancer

An unusual cause of renal tubular dysfunction in multiple myeloma